|
TERT rearrangements to identify a subset of aggressive meningiomas. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
Stock and Other Ownership Interests - Ignyta |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Lilly |
Travel, Accommodations, Expenses - Merck |
|
Priscilla Kaliopi Brastianos |
Honoraria - Angiochem; Genentech; Merck |
Consulting or Advisory Role - Genentech/Roche; Lilly |
Research Funding - Merck; Pfizer |